Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 26 Apr 2023
By using interpretation and translation to present information to communities in their native language, public health outreach initiatives frequently aim to break down communication barriers. However, bilingual people from various cultural backgrounds.
Read Full NewsThe phase 3 HARMONIA trial will evaluate whether a muscle- and CNS-targeted antisense conjugate improves function across multiple systems in patients with myotonic dystrophy type 1.
New data from the 2026 AANEM Annual Meeting showed zilucoplan delivered via autoinjector was bioequivalent to the pre-filled syringe and was well tolerated when self-administered by patients with generalized myasthenia gravis.
The ongoing phase 3 study is enrolling approximately 180 adults across more than 13 countries, with topline results expected in mid-2027.
EpilepsyGTx and Viralgen have entered a manufacturing collaboration to support development of EPY201, an investigational AAV9-based gene therapy for focal refractory epilepsy planned to enter first-in-human testing in 2027.
Phase 3 trials EMNERGIZE and EMVIGORATE will evaluate the efficacy and safety of intravenous empasiprubart in adults with chronic inflammatory demyelinating polyradiculoneuropathy.
The chairman of the Neurology Service Line at Baptist Health in Kentucky discussed PREVIEW trial findings for gefelorilimab in generalized myasthenia gravis, including efficacy, safety, and what the subcutaneous C5 inhibitor could offer patients if approved.
Lessons From 10,000 Organ Transplants, With Ari Cohen, MD
1.
Medication Self-Injection Embraced by Breast Cancer Patients
2.
The FDA Approves the New Frontline Aggressive ALL Regimen.
3.
Pirtobrutinib Delays Progression in CLL Already Treated With a BTK Inhibitor
4.
Childhood brain tumors develop early in highly specialized nerve cells, research reveals
5.
An effective treatment for a rare but deadly form of cancer
1.
Hemophilia: Pathophysiology, Genetics, and Treatment Advances
2.
A Closer Look at MCV Modules: Features, Functions, and Benefits
3.
The Importance of Early Detection in Angiosarcoma: A Story of Survival
4.
Exploring the Causes and Treatments of Thrombocytopenia: A Comprehensive Guide
5.
Understanding Purpura Fulminans: Causes, Symptoms and Treatment Options
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
4.
Navigating the Complexities of Ph Negative ALL - Part IV
5.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge